<DOC>
	<DOC>NCT01574885</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of Aerosal® compared to a placebo treatment in the prognosis of sub-obstructive adenotonsillar hypertrophy present for at least six months.</brief_summary>
	<brief_title>Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<criteria>SubObstructive Adenotonsillar Hypertrophy lasting from at least six months and associated with sleep disordered breathing (respiratory pauses or sleepapnea) and/or recurrent seromucus otitis Suspension for more than 3 months from the date of any immunosuppressive treatments (cyclosporin, systemic steroids) Patients with acute bronchopulmonary disease, tuberculosis, severe hypertension, hyperthyroidism, cancer (chemotherapy), intoxication, heart failure, bronchial asthma. Iodine allergy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>sleep apnea</keyword>
	<keyword>adenotonsillar hypertrophy</keyword>
	<keyword>salt</keyword>
	<keyword>sodium chloride</keyword>
</DOC>